News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrimack Pharmaceuticals Inc. Announces Expansion of Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer



6/28/2012 9:29:49 AM

CAMBRIDGE, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that it has expanded the global Phase 3 study of MM-398 versus an infusional regimen of 5-fluorouracil (5-FU) and leucovorin (folinic acid) (LV) in patients with metastatic pancreatic cancer where a gemcitabine-containing regimen has failed. The study has been expanded to include an additional arm which combines MM-398 with 5-FU and LV. The Phase 3 study, called NAPOLI-1 (NAnoliPOsomaL Irinotecan), is scheduled to begin enrollment on the amended protocol in July.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES